Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss
Merck and Daiichi Sankyo have pulled the biologics license application for their HER3 antibody-drug conjugate. The companies said Thursday that they voluntarily withdrew the accelerated approval request for
Merck and Daiichi Sankyo have pulled the biologics license application for their HER3 antibody-drug conjugate.
The companies said Thursday that they voluntarily withdrew the accelerated approval request for
